Mild to moderate scalp rashes caused by Tarceva can usually be easily controlled with over-the-counter and prescription medications if needed. If your scalp is dry and itchy, your doctor may recommend you use an OTC shampoo that targets dry scalp. Common brands include Paul Mitchell Tea Tree Shampoo or other shampoos containing tea tree oil, Selsun Blue, Head and Shoulders, or other dry scalp shampoos. Some people do find relief with OTC shampoos, but if not, your doctor may prescribe a shampoo -- Capex, Olux, and Nizoral are commonly prescribed shampoos.
When your scalp has pimples or pustules, there is a concern of an infection developing, especially if you are itching your scalp. Your doctor may prescribe an oral and/or topical antibiotic to help prevent infection from occurring. Antibiotics may not help prevent the rash from forming, but it may help with the severity. Your doctor may also recommend you use a cleanser on your scalp called Hibiclens, which is an antimicrobial soap that is most often used by doctors before surgery. It is an OTC product that costs about $10 for a 16 oz bottle. If you cannot find it on the shelf, ask the pharmacy at your local drugstore, as it may be stored behind the counter.
It is important that you notify your doctor immediately if you begin to develop a rash or if it begins to worsen. A rash caused by Tarceva can indicate that the treatment is working, but some people may develop severe rashes that require more aggressive medical intervention. Do not interpret the severity of the rash as an indicator of how well your body is responding to treatment. Keep your oncology nurse and doctor updated about your rash and notify them immediately of any new symptoms or if the rash is getting worse.
It is also vital to talk to your doctor or nurse before using any OTC or herbal treatment, even if it is a shampoo or lotion. Your oncology nurse can usually recommend products that are best for your personal needs. Before you buy any medication, always run it past your medical team.
More Tips for Coping With Rashes Caused by Tarceva
Sources:
American Cancer Society. Erlotinib. Accessed March 10, 2010.
http://www.cancer.org/docroot/CDG/content/CDG_erlotinib.asp
Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913-3921.
